References
Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010; 363 (18 Nov): 1981–5
College of Physicians and Surgeons of Ontario. Report of the Opioid Working Group. Avoiding abuse, achieving a balance: tackling the opioid public health crisis. Toronto (ON): College of Physicians and Surgeons of Ontario, 2010 Sep
He Q, Wang X, Xia Y, et al. New community-based methadone maintenance treatment programs in Guandong, China, and their impact on patient quality of life. Subst Use Misuse 2011; 46(6): 749–57
Hallinan R, Osborn N, Cohen M, et al. Increasing the benefits and reducing the harms of prescription opioid abuse. Drug Alcohol Rev 2011 May; 30(3): 315–23
Cornish R, Macleod J, Strang J, et al. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010; 341: C5475
Maremmani I, Gerra G. Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment. Am J Addiction 2010; 19 (Nov–Dec): 557–68
Krupitsky E, Woody GE, Zvartau E, et al. Addiction treatment in Russia [letter]. Lancet 2010; 376 (Oct): 1145
Basu D, Gaur N, Das PP, et al. Herbal medicines: perfect garb for opioid abuse? A case series from India. Am J Addiction 2010; 20: 174–5
Strain EC, Harrison JA, Bigelow GE. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble films. Clin Pharm Ther 2011; 89 (Mar): 443–9
Draper R. Opium wars. Natl Geogr 2011; 219: 58–83
Jones HE, O’Grady KE, Johnson RE, et al. Infant neurobehaviour following prenatal exposure to methadone or buprenorphine: results from the neonatal intensive care unit network neurobehavioral scale. Sub Use Misuse 2010; 45 (July): 2244–57
Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363: 2320–31
Seligman NS, Almario CV, Hayes EJ, et al. Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. J Pediatr 2010; 157: 428–33
Liu AJW, Jones MP, Murray H, et al. Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy. Aust N Z J Obstet Gynaecol 2010; 50: 253–8
Jansson LM, DiPietro JA, Elko A, et al. Infant autonomic functioning and neonatal abstinence syndrome. Drug Alcohol Depend 2010; 109: 198–204
Dashe J, Sheffield JS, Olscher DA, et al. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 2002; 100: 1244–9
Lim S, Prasad MR, Samuels P, et al. High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. Am J Obstet Gynecol 2009; 200: 70.e1–5
Berghella V, Lim PJ, Hill MK, et al. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol 2003; 189: 312–7
Kuschel CA, Austerberry L, Cornwell M, et al. Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome? Arch Dis Child Fetal Neonatal Ed 2004; 89: F390–3
Sarkar S, Donn SM. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol 2006; 26: 15–7
O’Grady MJ, Hopewell J, White MJ. Management of neonatal abstinence syndrome: a national survey and review of practice. Arch Dis Child Fetal Neonatal Ed 2009; 94: F249–52
Hoder EL, Leckman JF, Poulsen J, et al. Clonidine treatment of neonatal narcotic abstinence syndrome. Psychiatry Res 1984; 13: 243–51
Hunt RW, Tzioumi D, Collins E, et al. Adverse neurodevelopment outcome of infants exposed to opiate in-utero. Early Hum Dev 2008; 84: 29–35
Nanovskaya TN, Nekhayeva IA, Hankins GDV, et al. Transfer of methadone across the dually perfused preterm human placental lobule. Am J Obstet Gynecol 2008; 198: 126.e1–4
Nekhayeva IA, Nanovskaya TN, Deshmukh SV, et al. Bidirectional transfer of methadone across human placenta. Biochem Pharmacol 2005; 69: 187–97
Malek A, Obrist C, Wenzinger S, et al. The impact of cocaine and heroin on the placental transfer of methadone. Reprod Biol Endocrinol 2009; 7: 61
Gordon AL, Lopatko OV, Somogyi AA, et al. (R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. Br J Clin Pharmacol 2010; 70: 895–902
Kraft WK, Dysart K, Greenspan JS, et al. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction 2010; 106: 574–80
Agthe AG, Kim GR, Mathias KB, et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics 2009; 123: e849–56
Soyka M, Kranzler HR, van den Brink W, et al. The World Federation of Societies of Biological Psychiatry (WF SBP) guidelines for the biological treatment of substance use and related disorders: part 2. Opioid dependence. World J Biol Psychiatry 2011; 12: 160–87
Kakinohana M, Oshiro M, Saikawa S, et al. Intravenous infusion of dexmedetomidine can prevent the degeneration of spinal ventral neurons induced by intrathecal morphine after a noninjurious interval of spinal cord ischemia in rats. Anaesth Analg 2007; 105: 1086–93
Sanders RD, Sun P, Patel S, et al. Dexmedetomidine provides cortical neuroprotection: impact on anaesthetic-induced neuroapoptosis in the rat developing brain. Acta Anaesthesiol Scand 2010; 54: 710–6
Mitchell TB, Dyer KR, Newcombe D, et al. Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure. Br J Clin Pharmacol 2004; 58: 609–17
Elkader AK, Brands B, Dunn E, et al. Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. J Clin Psychopharmacol 2009; 29: 77–81
Eap CB, Crettol S, Rougier JS, et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 2007; 81: 719–28
McCance-Katz EF. (R)-methadone versus racemic methadone: what is best for patient care? Addiction 2011; 106: 687–8
Totah RA, Sheffels P, Roberts T, et al. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008; 108: 363–74
Bunten H, Liang WJ, Pounder DJ, et al. OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin Pharmacol Ther 2010; 88: 383–9
Yuferow V, Levran O, Proudnikov D, et al. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci 2010; 1187: 184–207
Wang JS, Ruan Y, Taylor RM, et al. Brain penetration of methadone (R)- and (S)- enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb 1a gene knockout mice. Psychopharmacology 2004; 173: 132–8
Piercefield E, Archer P, Kemp P, et al. Increase in unintentional overdose deaths -Oklahoma, 1994–2006. Am J Prev Med 2010; 39(4): 357–63
Rettig R. Federal regulation of methadone: table of contents and executive summary. Washington, DC: National Academy Press, 1995
Strain EC, Harrison JA, Bigelow GE. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. Clin Pharmacol Ther 2011; 89: 443–9
Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence. JAMA 2010; 304: 1576–83
Acknowledgements
The author has no conflicts of interest that are directly relevant to the content of this editorial.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Knoppert, D. The Worldwide Opioid Epidemic. Pediatr-Drugs 13, 277–279 (2011). https://doi.org/10.2165/11592700-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11592700-000000000-00000